A Modified γ-retrovirus Vector for X-linked Severe Combined Immunodeficiency

Background: In previous clinical trials involving children with X-linked severe combined immunodeficiency (SCID-X1), a Moloney murine leukemia virus-based γ-retrovirus vector expressing interleukin-2 receptor γ-chain (γc) complementary DNA successfully restored immunity in most patients but resulted in vector-induced leukemia through enhancer-mediated mutagenesis in 25% of patients. We assessed the efficacy and safety of a self-inactivating retrovirus for the treatment of SCID-X1.

Methods: We enrolled nine boys with SCID-X1 in parallel trials in Europe and the United States to evaluate treatment with a self-inactivating (SIN) γ-retrovirus vector containing deletions in viral enhancer sequences expressing γc (SIN-γc).

Results: All patients received bone marrow-derived CD34+ cells transduced with the SIN-γc vector, without preparative conditioning. After 12.1 to 38.7 months of follow-up, eight of the nine children were still alive. One patient died from an overwhelming adenoviral infection before reconstitution with genetically modified T cells. Of the remaining eight patients, seven had recovery of peripheral-blood T cells that were functional and led to resolution of infections. The patients remained healthy thereafter. The kinetics of CD3+ T-cell recovery was not significantly different from that observed in previous trials. Assessment of insertion sites in peripheral blood from patients in the current trial as compared with those in previous trials revealed significantly less clustering of insertion sites within LMO2, MECOM, and other lymphoid proto-oncogenes in our patients.

Conclusions: This modified γ-retrovirus vector was found to retain efficacy in the treatment of SCID-X1. The long-term effect of this therapy on leukemogenesis remains unknown. (Funded by the National Institutes of Health and others; ClinicalTrials.gov numbers, NCT01410019, NCT01175239, and NCT01129544.).

Citing Articles

Are monocytes a preferable option to develop myeloid cell-based therapies for solid tumors?.

Bhatia D, Dolcetti R, Mazzieri R J Exp Clin Cancer Res. 2025; 44(1):98.

PMID: 40089746 DOI: 10.1186/s13046-025-03359-x.

Viral-based gene therapy clinical trials for immune deficiencies and blood disorders from 2013 until 2023 - an overview.

Eshghi S, Mousakhan Bakhtiari M, Behfar M, Izadi E, Naji P, Jafari L Regen Ther. 2025; 28():262-279.

PMID: 39844821 PMC: 11751425. DOI: 10.1016/j.reth.2024.12.007.

Lentiviral Gene Therapy with CD34+ Hematopoietic Cells for Hemophilia A.

Srivastava A, Abraham A, Aboobacker F, Singh G, Geevar T, Kulkarni U N Engl J Med. 2024; 392(5):450-457.

PMID: 39655790 PMC: 11875532. DOI: 10.1056/NEJMoa2410597.

Age-associated imbalance in immune cell regeneration varies across individuals and arises from a distinct subset of stem cells.

Nogalska A, Eerdeng J, Akre S, Vergel-Rodriguez M, Lee Y, Bramlett C Cell Mol Immunol. 2024; 21(12):1459-1473.

PMID: 39443746 PMC: 11607082. DOI: 10.1038/s41423-024-01225-y.

Long-term lineage commitment in haematopoietic stem cell gene therapy.

Calabria A, Spinozzi G, Cesana D, Buscaroli E, Benedicenti F, Pais G Nature. 2024; 636(8041):162-171.

PMID: 39442556 PMC: 11618100. DOI: 10.1038/s41586-024-08250-x.

References

Noguchi M, Yi H, Rosenblatt H, Filipovich A, Adelstein S, Modi W . Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell. 1993; 73(1):147-57. DOI: 10.1016/0092-8674(93)90167-o. View

Hacein-Bey-Abina S, Garrigue A, Wang G, Soulier J, Lim A, Morillon E . Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest. 2008; 118(9):3132-42. PMC: 2496963. DOI: 10.1172/JCI35700. View

Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, Callegaro L . Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med. 2009; 360(5):447-58. DOI: 10.1056/NEJMoa0805817. View

Gaspar H, Parsley K, Howe S, King D, Gilmour K, Sinclair J . Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet. 2004; 364(9452):2181-7. DOI: 10.1016/S0140-6736(04)17590-9. View

Brady T, Roth S, Malani N, Wang G, Berry C, Leboulch P . A method to sequence and quantify DNA integration for monitoring outcome in gene therapy. Nucleic Acids Res. 2011; 39(11):e72. PMC: 3113588. DOI: 10.1093/nar/gkr140. View

Gaspar H, Cooray S, Gilmour K, Parsley K, Adams S, Howe S . Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency. Sci Transl Med. 2011; 3(97):97ra79. DOI: 10.1126/scitranslmed.3002715. View

Wang G, Berry C, Malani N, Leboulch P, Fischer A, Hacein-Bey-Abina S . Dynamics of gene-modified progenitor cells analyzed by tracking retroviral integration sites in a human SCID-X1 gene therapy trial. Blood. 2010; 115(22):4356-66. PMC: 2881494. DOI: 10.1182/blood-2009-12-257352. View

Gatti R, Meuwissen H, ALLEN H, Hong R, GOOD R . Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet. 1968; 2(7583):1366-9. DOI: 10.1016/s0140-6736(68)92673-1. View

Candotti F, Shaw K, Muul L, Carbonaro D, Sokolic R, Choi C . Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans. Blood. 2012; 120(18):3635-46. PMC: 3488882. DOI: 10.1182/blood-2012-02-400937. View

10.

Brown L, Xu-Bayford J, Allwood Z, Slatter M, Cant A, Davies E . Neonatal diagnosis of severe combined immunodeficiency leads to significantly improved survival outcome: the case for newborn screening. Blood. 2011; 117(11):3243-6. DOI: 10.1182/blood-2010-08-300384. View

11.

Cavazzana-Calvo M, de Saint Basile G, Gross F, Yvon E, Nusbaum P, Selz F . Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 2000; 288(5466):669-72. DOI: 10.1126/science.288.5466.669. View

12.

Antoine C, Muller S, Cant A, Cavazzana-Calvo M, Veys P, Vossen J . Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99. Lancet. 2003; 361(9357):553-60. DOI: 10.1016/s0140-6736(03)12513-5. View

13.

Deichmann A, Hacein-Bey-Abina S, Schmidt M, Garrigue A, Brugman M, Hu J . Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. J Clin Invest. 2007; 117(8):2225-32. PMC: 1934585. DOI: 10.1172/JCI31659. View

14.

Berry C, Ocwieja K, Malani N, Bushman F . Comparing DNA integration site clusters with scan statistics. Bioinformatics. 2014; 30(11):1493-500. PMC: 4029028. DOI: 10.1093/bioinformatics/btu035. View

15.

Hacein-Bey-Abina S, Le Deist F, Carlier F, Bouneaud C, Hue C, de Villartay J . Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med. 2002; 346(16):1185-93. DOI: 10.1056/NEJMoa012616. View

16.

Kustikova O, Fehse B, Modlich U, Yang M, Dullmann J, Kamino K . Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science. 2005; 308(5725):1171-4. DOI: 10.1126/science.1105063. View

17.

Pan W . Akaike's information criterion in generalized estimating equations. Biometrics. 2001; 57(1):120-5. DOI: 10.1111/j.0006-341x.2001.00120.x. View

18.

Schwarzwaelder K, Howe S, Schmidt M, Brugman M, Deichmann A, Glimm H . Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo. J Clin Invest. 2007; 117(8):2241-9. PMC: 1934556. DOI: 10.1172/JCI31661. View

19.

Buckley R, Schiff S, Schiff R, Markert L, Williams L, Roberts J . Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med. 1999; 340(7):508-16. DOI: 10.1056/NEJM199902183400703. View

20.

Berry C, Gillet N, Melamed A, Gormley N, Bangham C, Bushman F . Estimating abundances of retroviral insertion sites from DNA fragment length data. Bioinformatics. 2012; 28(6):755-62. PMC: 3307109. DOI: 10.1093/bioinformatics/bts004. View